Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 5/20 | 0.35 |
| ▸ | MMP3 | P08254 | 4/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6737490 | 0.85 | KCNH2 (0.41) | KDM1AKCNH2MMP2MMP3GRIN1 | |
| SCHEMBL6737941 | 0.82 | KCNH2 (0.52) | KCNH2 | |
| SCHEMBL6737171 | 0.82 | KCNH2 (0.52) | KCNH2 | |
| SCHEMBL6743285 | 0.81 | KCNH2 (0.43) | KDM1AKCNH2MMP2MMP3GRIN1 | |
| SCHEMBL6743295 | 0.77 | KCNH2 (0.49) | KDM1AKCNH2 | |
| SCHEMBL6737542 | 0.76 | KCNH2 (0.37) | KCNH2GPR119EGLN2CHRNA7HRH2 | |
| SCHEMBL6741109 | 0.76 | KCNH2 (0.51) | KDM1AKCNH2MMP2MMP3 | |
| SCHEMBL6739759 | 0.75 | GPR119 (0.35) | KCNH2GPR119ARGRIN1GRIN2B | |
| SCHEMBL6622413 | 0.75 | KCNH2 (0.48) | KCNH2GPR119EGLN2 | |
| SCHEMBL29388816 | 0.75 | KCNH2 (0.48) | KCNH2GPR119EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | KDM1A 4132/4885KCNH2 13/4885GPR119 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.